AACOMmunities

Federal Funding Opportunities and Resources

Below is a selected list of timely federal funding opportunities that are relevant to the osteopathic medical education community. AACOM updates this resource frequently.  Please bookmark the page for your reference. For a comprehensive listing of federal funding opportunities, please visit Grants.gov.   

The U.S. Department of Health and Human Services (HHS) has developed a Grant Opportunities and Guidance clearinghouse across all departments where you can find information about all aspects of the grant process during the COVID-19 crisis. For example, the NIH webpage provides  information and guidance about extensions, resubmissions, and funding opportunities related to COVID-19.  Its resources are also presented here, in a daily, updated format.

 

Featured Opportunities

 

April 2-29, 2022

National Institutes of Health

NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional)
Application Due Dates: August 19, 2022
The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce.

NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)
Application Due Dates: September 09, 2022
The NIH Director’s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce.

NIH Director’s Early Independence Awards (DP5 Clinical Trial Optional)
Letter of Intent Due Date(s): August 02, 2022
Application Due Dates: September 02, 2022
The NIH Director's Early Independence Award supports exceptional junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
Letter of Intent Due Date(s): July 05, 2022
Application Due Dates: August 05, 2022
This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD).

Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): Optional
Application Due Dates: July 29, 2022
Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to “Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts” PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship.

Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)
Application Due Dates: June 15, 2022
The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

Transition to Aging Research for Predoctoral Students (F99/K00 Clinical Trial Not Allowed)
Application Due Dates: October 21, 2022
This FOA seeks to foster the development of research and clinician scientists in the following areas: genetic, biological, clinical, epidemiological, neuroscientific, behavioral, social, and economic research on aging, both basic and translational.

Emergency Award: Rapid Acceleration of Diagnostics Tribal Data Repository (RADx TDR) (U24 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): May 1, 2022
Application Due Dates: May 31, 2022
This FOA seeks to fund a single RADx Tribal Data Repository (RADx TDR). The RADx TDR is intended to be an independent research data repository governed under the principles and practices of tribal sovereignty. The RADx TDR will provide responsible data sharing and access to researchers and their collaborators who are generating or interested in working with RADx American Indian and Alaska Native (AI/AN) research data.

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 17, 2022
This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional)
Letter of Intent Due Date(s): August 27, 2022
Application Due Dates: September 27, 2022
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to solicit applications for the Pediatric Immunotherapy Network (PIN). The overall goal of this FOA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors.

Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: July 29, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics and related countermeasures against antibiotic resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, or Candida auris.

Laboratories to Optimize Digital Health (R01 Clinical Trial Required)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 05, 2022
This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: July 01, 2022
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in Down syndrome.

Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: July 01, 2022
This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome.

Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)
Application Due Dates: July 01, 2022
This Funding Opportunity Announcement (FOA) is soliciting Transformative Research Award applications to support individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research that has the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies related to Down syndrome.

Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: July 01, 2022
This FOA is intended to support meritorious small research projects focused on analyses of genomics other -omics, clinical and phenotypic datasets related to Down syndrome research, with an emphasis on elucidating the underlying etiologies of risk and resiliencies to co-occurring health conditions.

National Institute of General Medical Sciences (NIGMS) Bridges to the Baccalaureate Research Training Program (T34)
Application Due Dates: September 26, 2022
The goal of the Bridges to the Baccalaureate Research Training Program is to provide structured activities to prepare a diverse cohort of research-oriented students to transfer from associate degree-granting institutions to baccalaureate degree-granting institutions and complete a baccalaureate degree in disciplines related to the biomedical sciences. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise.

Development and Optimization of Next-Generation Immunological Assays to Support Influenza Clinical Studies and Trials (UH2/UH3 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: July 01, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to develop and optimize next-generation immunological assays that will be readily utilized for influenza clinical studies and trials by the end of the UH2/UH3 project period.

Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required)
Application Due Dates: August 11, 2022
The purpose of the Funding Opportunity Announcement (FOA) is to support research that addresses limitations in understanding how to ensure all people who use drugs (PWUD) and are at risk for, or living with HIV have rapid access to high quality substance use disorder (SUD) treatment and HIV care services, including Pre-exposure prophylaxis (PrEP).

A Community Research Resource: Characterization of the Resident Ocular Microbiome. (U24 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): June 06, 2022
Application Due Dates: July 06, 2022
The overall purpose of this funding opportunity announcement (FOA) is to invite applicants from multidisciplinary research teams to develop a community-based resource of microbial data associated with the resident ocular microbiome of healthy individuals. The data include factors microbial communities elaborate that impact human physiology.

Alcohol Treatment and Recovery Research (R34 Clinical Trial Required)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 16, 2022
This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

Alcohol Health Services Research (R01 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 05, 2022
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD).

Alcohol Health Services Research (R34 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 16, 2022
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD).

Alcohol Treatment and Recovery Research (R01 Clinical Trial Required)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 05, 2022
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD).

Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: July 08, 2022
This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the Physical Sciences-Oncology Network (PS-ON) is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists.

Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)
Letter of Intent Due Date(s): June 17, 2022
Application Due Dates: July 19, 2022
The purpose of this FOA is to provide support for applications that propose a novel genome editing clinical trial that includes at least two different diseases, using the same genome editor, route of administration, and delivery system.

IND-enabling Studies of Somatic Genome Editing Therapeutic Leads (U19, Clinical Trial Not allowed)
Letter of Intent Due Date(s): June 17, 2022
Application Due Dates: July 19, 2022
This funding opportunity announcement (FOA) is part of a suite of FOAs of the NIH Common Fund Somatic Cell Genome Editing (SCGE) Phase II Program. The goal of this U19 FOA is to support team-based research Projects to accelerate further optimization and development of genome editing-based therapeutic leads towards IND-enabling studies and an IND (Investigational New Drug) application submission to the U.S. Food and Drug Administration (FDA).

Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed)
Letter of Intent Due Date(s): June 17, 2022
Application Due Dates: July 19, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications on the optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics.

Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the United States (R01 - Clinical Trial Required)
Letter of Intent Due Date(s): July 15, 2022
Application Due Dates: August 15, 2022
This initiative will support research projects that examine innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subgroups within primary care settings located in geographic areas with a high rate of new infections in the United States.

Somatic Cell Genome Editing Program Translational Coordination and Dissemination Center (TCDC) (U24 - Clinical Trial Not Allowed)
Letter of Intent Due Date(s): June 17, 2022
Application Due Dates: July 19, 2022
The purpose of this FOA is to support the establishment of a Translational Coordination and Dissemination Center (TCDC) for the NIH Somatic Cell Genome Editing (SCGE) Consortium. In its second phase (FY2023-2027), the SCGE program will accelerate the development of genome-editing therapeutic agents by: facilitating IND-enabling studies.

IDeA Clinical Research Resource Center (U24 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): August 26, 2022
Application Due Dates: September 26, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support an IDeA Clinical Research Resource Center (I-CRRC) that addresses two specific needs for increasing capacity to conducting clinical trials and complex observational studies in IDeA states.

NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required)
Application Due Dates: May 24, 2022
The NEI uses U01 cooperative agreement awards to support investigator-initiated early-stage clinical trials that are greater than minimal risk and typically are Phase I or II trials. The risk level of the U01 trial requires appropriate performance oversight and safety monitoring. For purposes of this FOA, the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. 

Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional)
Letter of Intent Due Date(s): June 28, 2022
Application Due Dates: July 28, 2022
This Funding Opportunity Announcement (FOA) invites applications for Cystic Fibrosis (CF) Research and Translation Core Centers. CF Research and Translation Core Centers are designed to support both basic and clinical research on Cystic Fibrosis.

Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
Application Due Dates: October 05, 2022
This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics/imaging.

Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
Application Due Dates: July 29, 2022
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications to support research in established cancer epidemiology cohort studies, defined as studies that have achieved their initial planned recruitment goal.

Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: August 03, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to enroll large, digitally-maintained cohorts of people with HIV-1 (PWH) in the United States who are not adequately virally suppressed. Applicants will need to employ sampling strategies that ensure meaningful enrollment of participants who report prior gaps in HIV care engagement and/or lack of sustained viral suppression (VS).

Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)
Letter of Intent Due Date(s): October 15, 2022
Application Due Dates: November 15, 2022
This Funding Opportunity Announcement (FOA) invites applications for Comprehensive Alcohol Research Centers using the P60 mechanism which requires a dissemination core to initiate and expand community education related to the activities of the center.

Specialized Alcohol Research Centers (P50 Clinical trial Optional)
Letter of Intent Due Date(s): October 15, 2022
Application Due Dates: November 15, 2022
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan.

Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): June 15, 2022
Application Due Dates: July 15, 2022
The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.

NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 22, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS).

Neuronal Vulnerability to Proteinopathies in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (R01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): June 15, 2022
Application Due Dates: July 15, 2022
The goal of this Funding Opportunity Announcement (FOA) is to define and characterize neuronal and glial cell populations that are vulnerable to Alzheimer's disease (AD) and AD-related dementias (ADRD) proteinopathies.

Demonstration Projects to Promote Use of Interoperable Health Records in Clinical Research (R01 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): September 18, 2022
Application Due Dates: October 18, 2022
This Funding Opportunity Announcement (FOA) solicits applications for three-year demonstration projects to study the feasibility of, and develop best practices for, using interoperable health information from older adult research participants. Applicants must partner with one or more actively funded research studies that are enrolling or re-consenting older adult participants.

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: June 09, 2022
This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development.

Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)
Letter of Intent Due Date(s): September 17, 2022
Application Due Dates: October 17, 2022
The goal of the Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) program is to provide support for early-career physician-scientists trained in medical or surgical specialties and early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research.

Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of Central Nervous System co-morbidities in people living with HIV (R21 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: November 18, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support studies to investigate mechanisms by which the gut microbiome and gut immune system modulates the brain functions, circuits, neurotransmitters, signaling pathways and synaptic plasticity in the context of HIV and Anti-retroviral therapy.

Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional)
Letter of Intent Due Date(s):
30 days prior to the application due date
Application Due Dates: August 11, 2022
This Funding Opportunity Announcement (FOA) supports research on the effects of HIV and addictive substances, acting independently or synergistically on blood brain barrier (BBB) structure and function and the involvement of these effects in HIV associated neuropathology.

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): July 10, 2022
Application Due Dates: August 10, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support a coordinating center (CC), which will coordinate research efforts across the NIDA funded longitudinal cohorts that address emerging and high priority research on HIV/AIDS in the context of substance use and substance use disorders (SUD).

NIAMS Rheumatic Diseases Research Resource-based Centers (P30 - Clinical Trial Not Allowed)
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Dates: September 13, 2022
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Resource-based Centers Program (P30) for rheumatic diseases research areas within its mission. The Resource-based Centers will provide critical research infrastructure, shared facilities, services, and/or resources to groups of investigators conducting research on rheumatic diseases.

Education Program on Translational Devices (R25 Clinical Trial Not Allowed)
Letter of Intent Due Date(s): June 29, 2022
Application Due Dates: July 29, 2022
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

Agency for Healthcare Research and Quality

Diagnostic Centers of Excellence: Partnerships to Improve Diagnostic Safety and Quality (R18)
Application Due Dates:
June 09, 2022
This Notice of Funding Opportunity Announcement (NOFO) invites applications for the development of Diagnostic Centers of Excellence (DCE).  The role of a DCE is to support a component of diagnostic care in an integrated cross-disciplinary health system.  Each DCE will develop expertise in one or two focus areas of diagnostic improvement.